Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foxy-5 Phase Ib in metastatic breast, colon, or prostate cancer
NCT02655952Phase 1Completed
- Sponsor
- WntResearch AB
- Start
- Apr 2016
- Primary completion
- Oct 2017
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of Foxy-5 in breast cancer, colon cancer and Metastatic Prostate Cancer (mPC), sponsored by WntResearch AB. Primary endpoint: Dose Limiting Toxicities at 6 months. Started Apr 2016; status: completed.
02
Drugs
Foxy-5
03
Conditions
breast cancercolon cancerMetastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT02655952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655952.